Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced a registered direct offering to institutional investors, with the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS, aiming to raise $8 million in gross proceeds. The offering, expected to close on January 29, 2024, also includes the issuance of unregistered warrants to purchase an equivalent number of ADSs, exercisable at $1.00 per ADS and valid for five years. H.C. Wainwright & Co. is the exclusive placement agent for this offering. The net proceeds are intended for general corporate purposes, including working capital, acquisitions, and research and development. The ADSs are offered under a shelf registration statement on Form F-3, effective since August 9, 2021. The warrants, along with the ADSs underlying them, are issued in a private placement and are not registered under the Securities Act, thus are subject to specific conditions for sale in the United States.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced a registered direct offering to institutional investors, with the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS, aiming to raise $8 million in gross proceeds. The offering, expected to close on January 29, 2024, also includes the issuance of unregistered warrants to purchase an equivalent number of ADSs, exercisable at $1.00 per ADS and valid for five years. H.C. Wainwright & Co. is the exclusive placement agent for this offering. The net proceeds are intended for general corporate purposes, including working capital, acquisitions, and research and development. The ADSs are offered under a shelf registration statement on Form F-3, effective since August 9, 2021. The warrants, along with the ADSs underlying them, are issued in a private placement and are not registered under the Securities Act, thus are subject to specific conditions for sale in the United States.
专业生物制药公司RedHill Biopharma Ltd. 宣布向机构投资者注册直接发行，以每股ADS0.80美元的价格出售1,000万股美国存托股票（ADS），旨在筹集800万美元的总收益。此次发行预计将于2024年1月29日结束，还包括发行未注册的认股权证，以购买同等数量的美国存托凭证，每份ADS的行使价格为1.00美元，有效期为五年。H.C. Wainwright & Co. 是本次发行的独家配售代理。净收益用于一般公司用途，包括营运资金、收购和研发。美国存托凭证是根据F-3表格的货架注册声明提供的，自2021年8月9日起生效。认股权证及其所依据的美国存托凭证以私募方式发行，未根据《证券法》注册，因此受美国特定的销售条件的约束。
专业生物制药公司RedHill Biopharma Ltd. 宣布向机构投资者注册直接发行，以每股ADS0.80美元的价格出售1,000万股美国存托股票（ADS），旨在筹集800万美元的总收益。此次发行预计将于2024年1月29日结束，还包括发行未注册的认股权证，以购买同等数量的美国存托凭证，每份ADS的行使价格为1.00美元，有效期为五年。H.C. Wainwright & Co. 是本次发行的独家配售代理。净收益用于一般公司用途，包括营运资金、收购和研发。美国存托凭证是根据F-3表格的货架注册声明提供的，自2021年8月9日起生效。认股权证及其所依据的美国存托凭证以私募方式发行，未根据《证券法》注册，因此受美国特定的销售条件的约束。
有用
没用